The Evolution of Insulin and How it Informs Therapy and Treatment Choices
Open accessThe DOI matches its Crossref record; 79 of the 82 references it cites were found in a registry or an index.
Abstract
Insulin has been available for the treatment of diabetes for almost a century, and the variety of insulin choices today represents many years of discovery and innovation. Insulin has gone from poorly defined extracts of animal pancreata to pure and precisely controlled formulations that can be prescribed and administered with high accuracy and predictability of action. Modifications of the insulin formulation and of the insulin molecule itself have made it possible to approximate the natural endogenous insulin response. Insulin and insulin formulations had to be designed to produce either a constant low basal level of insulin or the spikes of insulin released in response to meals. We discuss how the biochemical properties of endogenous insulin were exploited to either shorten or extend the time-action profiles of injectable insulins by varying the pharmacokinetics (time for appearance of insulin in the blood after injection) and pharmacodynamics (time-dependent changes in blood sugar after injection). This has resulted in rapid-acting, short-acting, intermediate-acting, and long-acting insulins, as well as mixtures and concentrated formulations. An understanding of how various insulins and formulations were designed to solve the challenges of insulin replacement will assist clinicians in meeting the needs of their individual patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 2. Structure of human insulin. A: Amino acid sequence of human insulin. B: Three-dimensional structure of insulin monomer (A-chain in purple; B-chain in green; protein data bank [PDB] ID = 1LPH), insulin dimer (PDB ID = 1LPH), and insulin hexamer (comprised of 3 dimers and 2 Zn2+) (PDB ID = 2INS). (https://www.rcsb.org/pdb/static.do?p=general_information/about_pdb/index.html); 1LPH, 2INS=PDB ID for respective structures)](https://figures.cochat.ai/paper-figures/47a9baa04bb54a408b711fbf0d4e6807/the-evolution-of-insulin-and-how-it-informs-therapy-and-treatment-choices-figure-2.jpg)
















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Regardless of the insulin delivery method (MDI vs CSII), glycemic control metrics, including A1C and CGM TIR, hypoglycemic events, QoL, and patient satisfaction are substantially improved when MDI or CSII is augmented with CGM, with better results when CSII is combined with CGM or integrated into AID systems, compared with using CGM.158,160,1129–1131”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Towards a goal of reducing the need for multiple daily injections, the first long-acting insulin was developed in the 1930s by H. C. Hagedorn. It was a suspension protamine zinc insulin that was based on the discovery that insulin action could be prolonged by adding protamine obtained from river trout semen106. The action of protamine zinc insulin lasted 24–36 h.”
From 100 years of insulin: celebrating the past, present and future of diabetes therapy (2021) · cites this paper as [106]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Basal insulin analogs were designed with prolonged duration of action and reduced pharmacodynamic variability compared with protamine-based (NPH) human insulin, while rapid-acting analogs were introduced with quicker onset and shorter duration than short-acting (”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These insulins reduce postprandial hyperglycemia but have otherwise not been shown to reduce HbA 1c or hypoglycemia to a greater extent than rapid-acting analogs (3).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Basal insulin analogs were designed with prolonged duration of action and reduced pharmacodynamic variability compared with protamine-based (NPH) human insulin, while rapid-acting analogs were introduced with quicker onset and shorter duration than short-acting (”
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818
Heise, T., Nosek, L., Rønn, B. B., Endahl, L., Heinemann, L., Kapitza, C., & Draeger, E. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1614 · Cited by 614
Bliss, M. (1982) · doi:10.1007/978-1-349-09612-1 · Cited by 524
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0739-z · Cited by 448 · cited 1×
“After injection and dilution of the phenolic preservative in the SC space, the dihexamers selfassociate, forming multihexamer complexes (60).”
BackgroundThe Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin
Havelund, S., Plum, A., Ribel, U., Jonassen, I., Vølund, A., Markussen, J., & Kurtzhals, P. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000036926.54824.37 · Cited by 429 · cited 1×
“The fatty acyl side chain also enables binding to serum albumin, a long-lived plasma protein, thus slowing the disposition of detemir to peripheral tissues and clearance from the body (53).”
BackgroundBecker, R. H. A., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., & Heise, T. (2015) · Diabetes Care · doi:10.2337/dc14-0006 · Cited by 407 · cited 1×
“A 3-fold concentrated version of insulin glargine was developed to prolong the duration of action when the results of 2 preliminary studies showed less diurnal variation in glucose-lowering activity with U-300 compared to the same dose of U-100 glargine (46).”
ResultGlucose Sensing in Pancreatic β-Cells
Schuit, F. C., Huypens, P., Heimberg, H., & Pipeleers, D. G. (2001) · Diabetes · doi:10.2337/diabetes.50.1.1 · Cited by 405
Human Insulin from Recombinant DNA Technology
Johnson, I. S. (1983) · Science · doi:10.1126/science.6337396 · Cited by 401
Cited by
Items 201–288 of 288
Formulation and characterization of insulin nanoclusters for a controlled release
Danielsen, M., Kempen, P. J., Andresen, T. L., & Urquhart, A. J. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123658
Protein Sequencing and Multi-Omics Data Analysis of Human Insulin
Kumari, U., & Bhatia, A. (2023) · International Journal for Research in Applied Science and Engineering Technology · doi:10.22214/ijraset.2023.55519
100 years of insulin: everything old is new again
Pham, T., & Gardner, A. W. (2023) · Australian and New Zealand College of Anaesthetists eBooks · doi:10.60115/11055/1184
Optimizing Glycemic Outcomes for Children with Type 1 Diabetes
Wu, V., Choleva, L., & Wilkes, M. A. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.09.002
Diabetes Care in the Oncologic Population
Presswala, L. S., Farooki, A., & Flory, J. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-44648-1_24
Hassan, S. F. U., Hussain, M. Z., Janjua, I. M., Salim, H., Javed, S., & Younas, M. T. (2024) · Pakistan Armed Forces Medical Journal · doi:10.51253/pafmj.v74i1.8855
Formulation and Evaluation of Polyherbal Antidiabetic Capsules
Geetha, K., Bhavani, V., Kiran, R., & Rao, T. (2024) · Journal of Advanced Scientific Research · doi:10.55218/jasr.2024150305
Lertwattanarak, R., Laotaveerungrueng, N., & Sriussadaporn, S. (2024) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2024.100187
Modern insulin treatment for type 2 diabetes
Grønlund, E., Lund, L., Vilsbøll, T., & Hædersdal, S. (2024) · Ugeskrift for Læger · doi:10.61409/v03240172
Design, Verification and Validation of a Dynamic Model for an Intramuscular Autoinjector
Magubane, N., Ngoepe, M., & Sivarasu, S. (2024) · Design of Medical Devices Conference (DMD) · doi:10.1115/dmd2024-1028
Diabetes Management with Current Guidelines.
Karadeniz, Y. (2023) · doi:10.69860/nobel.9786053359111.12
Agapoff, M. (2023) · theses.fr (ABES) · doi:10.70675/c49182aazd024z4a90z8280zcc85407e6164
Current Recommendations for Insulin Therapy in the Hospitalized Patient
Rochester-Eyeguokan, C. D., & Pincus, K. J. (2024) · Critical Care Nursing Clinics of North America · doi:10.1016/j.cnc.2024.05.004
What Primary Care Clinicians Need to Know About Once-Weekly Insulins
Shubrook, J. H. (2024) · Federal Practitioner · doi:10.12788/fp.0536
“25 Now, once-weekly basal insulin formulations are in late-stage development, with insulin icodec receiving a recommendation for marketing approval in Europe and an FDA decision expected soon.”
Rouland, A. (2024) · theses.fr (ABES) · doi:10.70675/6af70b1eze632z469ez88c8zdb045a5e78c6
(2022) · American Diabetes Association eBooks · doi:10.2337/9781580407700.ch03
Factores Asociados con el Abandono del Tratamiento Insulínico en Pacientes con Diabetes
Figueroa, J. G. J., Ramos, M. R., Durán, J. D. R., Zamora, M. F., & Brindiz, L. E. P. (2025) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v9i1.16024
Hawthorne, S. (2025) · Women in engineering and science · doi:10.1007/978-3-031-80348-2_1
Insulinoma in a patient with type 2 diabetes: A case report
Rad, S. G., Houshyar, J., & Mehrasa, P. (2025) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01513-x
Current trends in insulin therapy
Štechová, K. (2025) · Česká a slovenská farmacie · doi:10.36290/csf.2025.011
Recent research on the druggability properties of chemical modification of endogenous substances
Yuan, T., Xiao, S., & Zhou, D. (2025) · Scientia Sinica Chimica · doi:10.1360/ssc-2025-0168
Automating Insulin Dosing and Delivery: The Latest in Algorithms, Calculators, and Devices
Longo, R. R. (2025) · Diabetes Spectrum · doi:10.2337/dsi25-0006
Optimising cardiac surgery outcomes in people with diabetes: the OCTOPuS pilot feasibility study
Holt, R. I. G., Barnard-Kelly, K. D., Patel, M. A., Newland‐Jones, P., Luthra, S., Picot, J., Partridge, H., & Cook, A. (2025) · Health Technology Assessment · doi:10.3310/poyw3311
Inhaled insulin in diabetes management: a review of efficacy, safety, and patient-centered outcomes
Raj, A., Deshpande, S., Hegde, R., Desai, A. A., & Anand, S. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20252819
Kósa, D., Pető, Á., & Bácskay, I. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00020-2
Nolte, J., & Müssig, K. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01365-3
Alghamdi, H. S., Alanazi, Y. L. R., Alanazi, H. M. M., Hudayb, A. A. A. B., Mutairi, D. M. A., Alanzi, M. A., Shaabi, F. A. H., Almarghalani, H. A., Albayre, H. M. A., Alenazi, A. A., et al. (2024) · Saudi Journal of Medicine and Public Health · doi:10.64483/20251140
İlhanlı, N., Özçobanoğlu, S., & Gülkesen, K. H. (2025) · Marmara medical journal · doi:10.5472/marumj.1800324
Phytomediated Nanoparticles and Diabetes
Sharma, S., Gautam, G. J., Gaurav, P., & Mishra, B. (2025) · Springer eBooks · doi:10.1007/978-3-032-03604-9_17
Pawar, A. D., Rohile, S. B., & D., S. S. (2025) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-29628
Beyazıt, Y., Ertekin, Y. H., Kurtkulağı, Ö., & Pek, E. (2024) · doi:10.55094/holistence.237
Batth, J., Langworthy, B., Kumar, A. D., Alvear, A. B., Chow, L. S., & Kohlenberg, J. D. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.11.006
“30 This results in lipolysis and hepatic ketone production, with ketonemia developing within 6 hours.”
Korol, R., Even‐Ram, S., Molakandov, K., Puchinsky, D., Hemed, M., Mizrahi, N., Toledo, I., Lazar, D., Chebath, J., Tritel, M., et al. (2025) · Hormone and Metabolic Research · doi:10.1055/a-2734-1983
Abordaje Integral de Enfermería Crítica en UCI
Sánchez, K. J. A., Solis, J. D. A., Rubio, K. E. B., Chávez, M. A. C., Cuascota, S. L. C., Chala-Minda, T. R., Sánchez, M. B. C., González, Y. E., Valencia, K. Y. E., Asadovay, M. Y. G., et al. (2025) · doi:10.56470/978-9942-568-84-7
Scn9a Na⁺ channels in beta-cell survival and type 1 diabetes
Overby, P. (2023) · cIRcle (University of British Columbia) · doi:10.14288/1.0435550
Incretin-based drugs and the incidence of endometrial cancer among patients with type 2 diabetes
Rothman, S. (2025) · eScholarship@McGill (McGill) · doi:10.82308/49186
Centenaro, A. (2021) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
DIABETE E OBESITÀ: IL RUOLO DELL'AMILINA
BARBIERI, D. (2024) · Electronic Theses and Dissertations Repository (University of Pisa)
Cabrera, A. (2023) · DUGiDocs (Universitat de Girona)
Jurado, A. L. (2025) · Repositorio Institucional de la Universidad de Málaga (University of Málaga)
Toluay, E. (2021) · Unipub UB Graz (Universität Graz)
Alcelay Uribeecheverría, A. (2023) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid)
Gorini, A. (2025) · Electronic Theses and Dissertations Repository (University of Pisa)
Farmasötik İlaçlar İçin Non invasif Kalite Kontrol Yöntemlerinin Tasarlanması
ALAM, H. (2024) · OpenMETU (Middle East Technical University)
Cabral, M. F. R. (2022) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Pothuraju, R., Susmitha, A., Meriga, P. K., Bandi, P., Eri, G. K., & Dugasani, S. R. (2025) · Oriental Journal Of Chemistry · doi:10.13005/ojc/410602
Cruz, T. A. P., & de Freitas, L. F. (2026) · DELOS Desarrollo Local Sostenible · doi:10.55905/rdelosv19.n76-011
Noronha, H. G. R. (2024) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Musse, T. N. M. [. (2024) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Insulina inalável: desenvolvimento de dispositivo tecnológico
Matos, I. L. S. (2024) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Chowdhury, S. A., Sh, L., Lee, Y.-K., & Park, J. (2026) · IEEE Access · doi:10.1109/access.2026.3659181
“The parameter ratio i [39] defines the proportion of long-acting to rapid-acting insulin dose. and 0 otherwise.”
Glycemic management in adults with type 1 diabetes
Koliaki, C. C., & Liatis, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00317-4
NEW FORMS AND TECHNOLOGIES OF INSULIN THERAPY IN TYPE 1 DIABETES - A SYSTEMATIC LITERATURE REVIEW
Ogorek, A., Kaniak, A., Andrzejewska, J., Wińska, A., Pietruszewska, H., Czerepak, I., Majchrzak, I., Ziemba, M., Zackiewicz, K., & Zielska, J. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4479
Buitrago-González, T. P., Arsanios, D. M., & Franco, J. J. P. (2026) · Acta Colombiana de Cuidado Intensivo · doi:10.1016/j.acci.2026.100592
Nasution, U. J., Astuti, R. I., Wahyudi, A. T., Hardianto, D., & Martius, E. (2026) · Journal of Multidisciplinary Applied Natural Science · doi:10.47352/jmans.2774-3047.368
Rodriguez, D. V. C., & Herrera, M. E. N. (2026) · Universidad Peruana Cayetano Heredia Institutional Repository
Kaddour, N. (2025) · Dépôt Institutionnel de lUniversité de Tlemcen
Nanofitine, module de transport actif pour l'administration orale de biomédicaments
Masloh, S. (2022) · theses.fr (ABES) · doi:10.70675/84e28fcaz05c1z4135z82f9zdb218a7a4969
Akhtar, M. N. (2023) · Qucosa (Saxon State and University Library Dresden)
Adejumo, I. A., Fageyinbo, M. S., Usman, S. O., Success, O. O., Amanda, U. N., Oluwaseun, O. T., Oreagba, I. A., & Agbaje, E. O. (2026) · Trends in Natural Products Research · doi:10.61594/tnpr.v7i2.2026.167
Nanosystems to Improve the Delivery of Biologicals
Raza, A., & Wu, W. (2025) · Springer handbooks · doi:10.1007/978-3-032-01636-2_7
Rohilla, K. K., Bhardwaj, Y., & Pandey, M. K. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c00157
Minimal-Data Peptide Design and Accessible Protein Language Models for Protein Engineering
Bayat, P. (2025) · TSpace (University of Toronto)
Switchable pathways for precise carboxylic acid modification in proteins and antibodies
Molla, R., Singudas, R., Biswas, D., Ojha, L., Bindra, D., Rai, S., Ragendu, V., Mukherjee, S., Mishra, R. K., & Rai, V. (2026) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2026.103340
Adults with Type 1 Diabetes and Insulin-Requiring Type 2 Diabetes
Hormachea, S. (2026) · American Diabetes Association eBooks · doi:10.2337/9781580408493-ch06
Myers, L. (2026) · TigerPrints (Clemson University)
Biosimilar insulin glargine: a solution for affordable and equitable diabetes care
Kumar, H., Gopal, J., Shamanna, P., Hasnani, D., Chavda, V., Prajapati, H. K., & Papaiya, H. V. (2026) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20261888
Peptide Hormones in Appetite Regulation: A Complex Network
Abdollahi, S., Adam, H., & Musaimi, O. A. (2026) · Pharmaceuticals · doi:10.3390/ph19070989
Current diabetes drugs: Lessons learned and implications for next-generation therapeutics
Liao, J., Cong, Z., Liu, K., Que, H., & Liu, F. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100008
Article Review: Herbs for Bone Growth Process
Rizky, A., Elya, B., & Fadilah, F. (2026) · Pharmacon Jurnal Farmasi Indonesia · doi:10.23917/pharmacon.v23i1.7584
Zanbili, F., Asadzadeh, F., & Marjani, A. P. (2026) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2026.117207
Yang, Y., Dhayalan, B., Ehnbom, A., Weil‐Ktorza, O., Metanis, N., & Weiss, M. A. (2026) · Protein Science · doi:10.1002/pro.70697
“Fibrillation constrains the formulation and shelf lives of insulin analogs designed to optimize pharmacokinetic properties (Figure S3) (Hirsch et al. 2020; see sect.”
Characterizing Novel Mimetic Peptides for Reducing Cardiovascular Disease
Ogunmodede, O. S. (2026) · UNSWorks (University of New South Wales, Sydney, Australia) · doi:10.26190/unsworks/32588
Type 2 diabetes management: weekly combination therapy comes of age?
Bellary, S., Karamat, M. A., & Barnett, A. H. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00165-8
Microneedle technology for diabetes therapy
Wang, W., & Wu, C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45544-5.00009-9
Talbo, M. K., Katz, A., Roy‐Fleming, A., Haag, S. C., Peters, T. M., RABASA-LHORET, R. P. R., Yale, J., Kelly, B., Moisan, J. M., & Brazeau, A. (2026) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2026.07.006
Xu, J., Li, Z., Liu, D., Zhao, L., & Li, Y. (2026) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2026.85
Franklin, D., Mahony, J., Patel, C., & Triay, J. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02795-1
Adamlje, E. (2026) · Repository of the University of Ljubljana (University of Ljubljana)
Diabetes Mellitus and Antidiabetic Medications
Mirrakhimov, A. E. (2026) · Springer eBooks · doi:10.1007/978-3-032-29397-8_113
Letramento digital em saúde em pessoas com diabetes mellitus tipo 1 no Brasil
de Abreu, M. C. F. (2023) · RIUnB Institutional Repository (University of Brasília) · doi:10.26512/2023.06.d.55822
Zaheer, M. H., Manzar, M. A., Ahmed, B., Tahir, R., Qureshi, M. H., & Akhtar, S. (2026) · Pakistan Armed Forces Medical Journal · doi:10.51253/pafmj.v76isuppl-9.8997
Miraculous Therapy for Diabetes: Use of Omega-3-Fatty Acids
Abroo Fatima Qazi, S. P. S. (2023) · Medical Forum Monthly
Balancing Cost and Access: The Pharmacoeconomic Challenge of Insulin Therapy in Diabetes Management
Mantri, P. (2022) · Innovations in Pharmacy Planet
Current options in insulin therapy
Krystyník, O. (2026) · Klinická farmakologie a farmacie · doi:10.36290/far.2026.026
Metadata
- Authors
- Hirsch, I. B., Juneja, R., Beals, J. M., Antalis, C. J., & Wright, E. E.
- Affiliations
- University of Washington (US)
- Eli Lilly (United States) (US)
- Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California
- Charlotte Area Health Education Center, Charlotte, North Carolina
- Corresponding author
- Hirsch, Irl B
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2020-05-12
- Volume
- 41
- Issue
- 5
- Pages
- 733-755
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC7366348
- OpenAlex
- W3024580742
- Cited by
- 237
- References
- 82
- Citations by year
- 2026: 25 · 2025: 50 · 2024: 37 · 2023: 37 · 2022: 45 · 2021: 38 · 2020: 4
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Endocrine Reviews (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- insulin, insulin formulations, insulin analogues, rapid-acting insulin, long-acting insulin, short-acting insulin, intermediate-acting insulin, insulin mixtures, insulin levels, pharmacokinetics, pharmacodynamics, endogenous insulin, diabetes treatment, insulin replacement therapy
- MeSH terms
- Diabetes Mellitus, Humans, Hypoglycemic Agents, Insulins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.